[1] Bonotto M, Bozza C, Di Loreto C, et al. Making capecitabine targeted therapy for breast cancer:which is the role of thymidine phosphorylase?[J]. Clin Breast Cancer, 2013, 13(3):167-172. [2] 孙强.对乳腺癌新辅助化疗的理解与遵循原则[J].临床药物治疗杂志,2010,8(6):3-8. [3] Zhang M, Wei W, Liu JL, et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer[J]. Onco Target Ther, 2016, 9:3443-3450. [4] Li QY, Jiang Y, Wei W, et al. Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer:a systematic review and meta-analysis of randomized controlled trials[J]. PLoS One, 2013, 8(1):e53403. [5] Lu YS, Chen DR, Tseng LM, et al. Phase Ⅱ study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer[J]. Cancer Chemother Pharmacol, 2011, 67(6):1257-1263. [6] Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer:an open-label, randomised controlled trial[J]. Lancet Oncol, 2009, 10(12):1145-1151. [7] Steger GG, Greil R, Lang A, et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer:final results of a randomized phase Ⅲ study (ABCSG-24)[J]. Ann Oncol, 2014, 25(2):366-371. [8] Ohno S, Chow LW, Sato N, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamid(FEC) in early-stage breast cancer:exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2013, 142(1):69-80. [9] Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer:the randomized clinical finXX trial[J]. JAMA Oncol, 2017,3(6):793-800. [10] Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40[NRG Oncology]):secondary outcomes of a phase 3, randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1037-1048. [11] O'Shaughnessy J, Koeppen H, Xiao Y, et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase Ⅲ adjuvant trial of capecitabine[J]. Clin Cancer Res, 2015, 21(19):4305-4311. [12] von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer:phase Ⅲ Gepar Quattro study[J]. J Clin Oncol, 2010, 28(12):2015-2023. [13] Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al.Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer:final analysis of the randomized FinXX trial[J]. J Clin Oncol, 2012, 30(1):11-18. [14] Kelly CM, Green MC, Broglio K, et al. Phase Ⅲ trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer[J]. J Clin Oncol, 2012, 30(9):930-935. [15] Bear HD, Tang G, Rastogi P, et al. Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer[J]. N Engl J Med, 2012, 366(4):310-320. [16] 李亚丽,肖佳灵,杨克虎,等.卡培他滨联合多烯紫杉醇治疗转移性乳腺癌的系统评价[J].中国循证医学杂志,2009, 9(8):893-898. [17] 黄雅娟,杜峰,魏玲丽.老年乳腺癌的流行病学研究及其对行根治性手术治疗患者生存期的影响[J].中国老年学杂志,2015,35(13):3653-3655. |